NCT07516561Phase 3Not yet recruiting
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
Phase III Randomized, Multicenter, Double-blind, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
In the register
The register attaches this trial to APSMNF (Apsen Farmacêutica), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Not yet recruiting
- Declared phase
- Phase 3
- Sponsor
- Apsen Farmaceutica S.A.
- Participants (registry)
- 336
- Start
- October 2026 (planned)
- Primary completion
- August 2029 (planned)
- Study completion
- August 2029 (planned)
- Last registry update
- September 2026
- Countries
- Brazil
Conditions studied: Alopecia, Androgenetic
Interventions: APSMNF 1, APSMNF 2, Eniagor®
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.